Combining Oncolytic Immunotherapy With Checkpoint Inhibitors Could Affect Cure
Ongoing clinical trials are evaluating a new immunotherapeutic approach for the treatment of malignant melanoma–the combination of an oncolytic virus with checkpoint inhibition.